Plasma pentraxin 3 is associated with progression of radiographic joint damage, but not carotid atherosclerosis, in female rheumatoid arthritis patients: 3-year prospective study

References

• Myasoedova E, Davis JM, 3rd, Crowson CS, Gabriel SE. Epidemiology of rheumatoid arthritis: rheumatoid arthritis and mortality. Curr Rheumatol Rep. 2010;12(5):379–85.
   PubMedGoogle Scholar
• Meune C, Touzé E, Trinquart L, Allanore Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford). 2009;48(10):1309–13.
   PubMed Web of Science ®Google Scholar
• Chung CP, Oeser A, Raggi P, Gebretsadik T, Shintani AK, Sokka T. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum. 2005;52(10):3045–53.
   PubMedGoogle Scholar
• Roman MJ, Moeller E, Davis A, Paget SA, Crow MK, Lockshin MD, et al. Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med. 2006;144(4):249–56.
   PubMed Web of Science ®Google Scholar
• Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362(6423):801–9.
   PubMed Web of Science ®Google Scholar
• Pasceri V, Yeh ET. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation. 1999;100(21):2124–6.
   PubMed Web of Science ®Google Scholar
• Wållberg-Jonsson S, Cvetkovic JT, Sundqvist K-G, Lefvert AK, Rantapää-Dahlqvist S. Rantapää-Dahlqvist S. Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis. J Rheumatol. 2002;29(5):875–82.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Garlanda C, Doni A, Bottazzi B. Pentraxins in innate immunity: from C-reactive protein to the long pentraxin PTX3. J Clin Immunol. 2008;28(1):1–13.
   PubMed Web of Science ®Google Scholar
• Deban L, Jaillon S, Garlanda C, Bottazzi B, Mantovani A. Pentraxins in innate immunity: lessons from PTX3. Cell Tissue Res. 2011;343(1):237–49.
   PubMed Web of Science ®Google Scholar
• Lee E-J, Song D-H, Kim Y-J, Choi B, Chung Y-H, Kim S-M, et al. PTX3 stimulated osteoclastogenesis by increasing osteoblast RANKL production. J Cell Physiol. 2014;229(11):1744–52.
   PubMed Web of Science ®Google Scholar
• Grčević D, Sironi M, Valentino S, Deban L, Cvija H, Inforzato A, et al. The long pentraxin 3 plays a role in bone turnover and repair. Front Immunol. 2018;9:417.
   PubMed Web of Science ®Google Scholar
• Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2002;22(5):e10–4.
   PubMed Web of Science ®Google Scholar
• Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Avanzini F, et al. PTX3, a prototypic long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 2000;102(6):636–41.
   PubMed Web of Science ®Google Scholar
• Inoue K, Sugiyama A, Reid PC, Ito Y, Miyauchi K, Mukai S, et al. Establishment of a high sensitivity plasma assay for human pentraxin 3 as a marker for unstable angina pectoris. Atvb. 2007;27(1):161–7.
   Google Scholar
• Luchetti MM, Piccinini G, Mantovani A, Peri G, Matteucci C, Pomponio G, et al. Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA). Clin Exp Immunol. 2000;119(1):196–202.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, Mc Shane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24.
   PubMed Web of Science ®Google Scholar
• Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81.
   PubMed Web of Science ®Google Scholar
• Teramoto T, Sasaki J, Ishibashi S, Birou S, Daida H, Dohi S, et al. Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan -2012 version. J Atheroscler Thromb. 2013;20(6):517–23.
   PubMed Web of Science ®Google Scholar
• Prevoo MLL, Van'T Hof MA, Kuper HH, Van Leeuwen MA, Van De Putte LBA, Van Riel PLCM. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of a patients with rheumatoid arthritis. Arthritis Rheum. 1995;38(1):44–8.
   PubMed Web of Science ®Google Scholar
• van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000;27(1):261–3.
   PubMed Web of Science ®Google Scholar
• Handa N, Matsumoto M, Maeda H, Hougaku H, Ogawa S, Fukunaga R, et al. Ultrasonic evaluation of early carotid atherosclerosis. Stroke 1990;21(11):1567–72.
   PubMed Web of Science ®Google Scholar
• Tekeoğlu İ, Harman H, Sağ S, Altındiş M, Kamanlı A, Nas K. Levels of serum pentraxin 3, IL-6, fetuin A and insulin in patients with rheumatoid arthritis. Cytokine 2016;83:171–5.
   PubMed Web of Science ®Google Scholar
• Weitoft T, Larsson A, Saxne T, Manivel VA, Lysholm J, Knight A, et al. Pentraxin 3 in serum and synovial fluid of patients with rheumatoid arthritis with and without autoantibodies. Scand J Rheumatol. 2017;46(5):346–52.
   PubMed Web of Science ®Google Scholar
• Sharma A, Khan R, Gupta N, Sharma A, Zaheer MS, Abbas M, et al. Acute phase reactant, pentraxin 3, as a novel marker for the diagnosis of rheumatoid arthritis. Clin Chim Acta. 2018;480:65–70.
   PubMed Web of Science ®Google Scholar
• Anuurad E, Enkhmaa B, Gungor Z, Zhang W, Tracy RP, Pearson TA, et al. Age as a modulator of inflammatory cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2011;31(9):2151–6.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Finkelstein JS, Shadick N, LeBoff MS, Winalski CS, Stedman M, et al. The relationship between focal erosions and generalized osteoporosis in postmenopausal women with rheumatoid arthritis: the Osteoporosis in Rheumatoid Arthritis (OPiRA) cohort study. Arthritis Rheum. 2009;60(6):1624–31.
   PubMedGoogle Scholar
• Barksby HE, Hui W, Wappler I, Peters HH, Milner JM, Richards CD, et al. Interleukin-1 in combination with oncostatin M up-regulates multiple genes in chondrocytes: implications for cartilage destruction and repair. Arthritis Rheum. 2006;54(2):540–50.
   PubMedGoogle Scholar
• Cawston TE, Curry VA, Summers CA, Clark IM, Riley GP, Life PF, et al. The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint. Arthritis Rheum. 1998;41(10):1760–71.
   PubMedGoogle Scholar
• Hui W, Cawston TE, Richards CD, Rowan AD. A model for inflammatory arthritis highlights a role for oncostatin M in pro‐inflammatory cytokine‐induced bone destruction via RANK/RANKL. Arthritis Res Ther. 2005;7(1):R57–64.
   PubMed Web of Science ®Google Scholar
• Rowan AD, Hui W, Cawston TE, Richards CD. Adenoviral gene transfer of interleukin‐1 in combination with oncostatin M induces significant joint damage in a murine model. Am J Pathol. 2003;162(6):1975–84.
   PubMed Web of Science ®Google Scholar
• Yokota K, Miyoshi F, Sato K, Asanuma Y, Akiyama Y, Mimura T. Geranylgeranyl-pyrophosphate regulates secretion of pentraxin 3 and monocyte chemoattractant protein-1 from rheumatoid fibroblast-like synoviocytes in distinct manners. Clin Exp Rheumatol. 2011;29(1):43–9.
   PubMed Web of Science ®Google Scholar
• Deyab G, Hokstad I, Whist JE, Småstuen MC, Agewall S, Lyberg T, et al. Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. PLoS One. 2017;12(2):e0169830.
   PubMed Web of Science ®Google Scholar
• Manabe N, Oda H, Nakamura K, Kuga Y, Uchida S, Kawaguchi H. Involvement of fibroblast growth factor-2 in joint destruction of rheumatoid arthritis patients. Rheumatology (Oxford). 1999;38(8):714–20.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, Taniguchi A, et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum. 2000;43(4):852–8.
   PubMed Web of Science ®Google Scholar
• Doria A, Iaccarino L, Ghirardello A, Zampieri S, Arienti S, Sarzi-Puttini P, et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med. 2006;119(8):700–6.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37(4):481–94.
   PubMed Web of Science ®Google Scholar
• del Rincón ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001;44:2737–45.
   PubMed Web of Science ®Google Scholar
• Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001;44(10):2331–7.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum. 2005;35(1):8–17.
   PubMed Web of Science ®Google Scholar
• Mavrogeni S, Dimitroulas T, Bucciarelli-Ducci C, Ardoin S, Sfikakis PP, Kolovou G, et al. Rheumatoid arthritis: an autoimmune disease with female preponderance and cardiovascular risk equivalent to diabetes mellitus: role of cardiovascular magnetic resonance. Inflamm Allergy Drug Targets. 2014;13(2):81–93.
   PubMedGoogle Scholar
• Kahlow BS, Petisco R, Skare TL, Goeldner I, Nisihara RM, Messias-Reason IJT. Messias-Reason IJ. Serum pentraxin 3 levels are negatively associated with carotid intima media thickness in non-obese rheumatoid arthritis patients. Int J Cardiol. 2016;221:298–301.
   PubMed Web of Science ®Google Scholar
• Soeki T, Niki T, Kusunose K, Bando S, Hirata Y, Tomita N, et al. Elevated concentrations of pentraxin 3 are associated with coronary plaque vulnerability. J Cardiol. 2011;58(2):151–7.
   PubMed Web of Science ®Google Scholar
• Hakimi M, Hyhlik-Dürr A, von Au A, Betz M, Demirel S, Dihlmann S, et al. The expression of glycophorin a and osteoprotegerin is locally increased in carotid atherosclerotic lesions of symptomatic compared to asymptomatic patients. Int J Mol Med. 2013;32(2):331–8.
   PubMed Web of Science ®Google Scholar
• Baragetti A, Knoflach M, Cuccovillo I, Grigore L, Casula M, Garlaschelli K, et al. Pentraxin 3 (PTX3) plasma levels and carotid intima media thickness progression in the general population. Nutr Metab Cardiovasc Dis. 2014;24(5):518–23.
   PubMed Web of Science ®Google Scholar
• Shimada Y, Asanuma YF, Yokota K, Yoshida Y, Kajiyama H, Sato K, et al. Pentraxin 3 is associated with disease activity but not atherosclerosis in patients with systemic lupus erythematosus. Mod Rheumatol. 2014;24(1):78–85.
   PubMed Web of Science ®Google Scholar